{"url_path":"/sec/vvos/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits, Financial Statement Schedules.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-024650-index.html","accession_number":"0001493152-26-024650","cik":"0001716166","ticker":"VVOS","issuer_name":"Vivos Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1716166/0001493152-26-024650-index.html","primary_entity_key":"0001716166","primary_entity_name":"Vivos Therapeutics, Inc."},"word_count":428,"has_tables":true,"body_markdown":"**Item\n6. Exhibits, Financial Statement Schedules.**\n\n \n\nThe\nfollowing documents are filed as exhibits to this Quarterly Report on Form 10-Q.\n\n \n\n**Exhibit\nNo.**\n \n**Exhibit\nDescription**\n\n \n \n \n\n3.1\n \n[Certificate\nof Incorporation of Vivos Therapeutics, Inc. filed with Delaware Secretary of State on August 12, 2020. (1)](https://www.sec.gov/Archives/edgar/data/1716166/000149315220019231/ex3-1.htm)\n\n \n \n \n\n3.2\n \n[Amended\nand Restated Bylaws of Vivos Therapeutics, Inc. (1)](https://www.sec.gov/Archives/edgar/data/1716166/000149315220019231/ex3-2.htm)\n\n \n \n \n\n3.3\n \n[Certificate\nof Conversion filed with Delaware Secretary of State on August 12, 2020. (1)](https://www.sec.gov/Archives/edgar/data/1716166/000149315220019231/ex3-3.htm)\n\n \n \n \n\n3.4\n \n[Certificate of Amendment to the Certificate of Incorporation of Vivos Therapeutics, Inc., dated October 25, 2023.(2)](https://www.sec.gov/Archives/edgar/data/1716166/000149315223038523/ex3-1.htm)\n\n \n \n \n\n31.1\n \n[Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (*)](ex31-1.htm)\n\n \n \n \n\n31.2\n \n[Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (*)](ex31-2.htm)\n\n \n \n \n\n32.1\n \n[Certification of the Chief Executive Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (*)#](ex32-1.htm)\n\n \n \n \n\n32.2\n \n[Certification of the Chief Financial Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (*)#](ex32-2.htm)\n\n \n \n \n\n101.INS*\n \nInline\nXBRL Instance Document\n\n \n \n \n\n101.SCH*\n \nInline\nXBRL Taxonomy Extension Schema Document\n\n \n \n \n\n101.CAL*\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n \n \n \n\n101.DEF*\n \nInline\nXBRL Taxonomy Extension Definition Linkbase Document\n\n \n \n \n\n101.LAB*\n \nInline\nXBRL Taxonomy Extension Label Linkbase Document\n\n \n \n \n\n101.PRE*\n \nInline\nXBRL Taxonomy Extension Presentation Linkbase Document\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).\n\n \n\n*\n\n \nFiled\nherewith\n\n \n \n \n\n(1)\n \nIncorporated\nby reference to the Company’s Registration Statement on Form S-1, filed with the SEC on October 9, 2020.\n\n \n \n \n\n(2)\n \nIncorporated\nby reference to the Company’s Current Report on Form 8-K, filed with the SEC on October 27, 2023.\n\n \n \n \n\n#\n \nA\nsigned original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company\nand furnished to the Securities and Exchange Commission or its staff upon request.\n\n \n\n44\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.\n\n \n\n \n**Vivos\nTherapeutics, Inc.**\n\n \n \n \n\nDate:\nMay 20, 2026\nBy:\n*/s/\nR. Kirk Huntsman*\n\n \n \nR.\nKirk Huntsman\n\n \n \nChairman\nof the Board and Chief Executive Officer\n\n \n \n(principal\nexecutive officer)\n\n \n \n \n\nDate:\nMay 20, 2026\nBy:\n*/s/\nBradford Amman*\n\n \n \nBradford\nAmman\n\n \n \nChief\nFinancial Officer and Secretary\n\n \n \n(principal\naccounting officer)\n\n \n\n45"}